Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: Consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology

被引:111
作者
Gao, Xin [1 ]
Fan, Jian-Gao [2 ]
机构
[1] Fudan Univ, Zhongshan Hosp, Dept Endocrinol & Metab, Shanghai 200032, Peoples R China
[2] Xinhua Hosp, Dept Gastroenterol, Shanghai, Peoples R China
关键词
NAFLD; metabolic disorders; diagnosis; management; MAGNETIC-RESONANCE-SPECTROSCOPY; PLACEBO-CONTROLLED TRIAL; NONINVASIVE ASSESSMENT; CLINICAL-SIGNIFICANCE; SERUM AUTOANTIBODIES; HEPATIC STEATOSIS; ADVANCED FIBROSIS; AMERICAN-COLLEGE; NATURAL-HISTORY; RISK-FACTOR;
D O I
10.1111/1753-0407.12056
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in Western countries, affecting 20%-33% of the general population. Large population-based surveys in China indicate a prevalence of approximately 15%-30%. Worldwide, including in China, the prevalence of NAFLD has increased rapidly in parallel with regional trends of obesity, type2 diabetes and metabolic syndrome. In addition, NAFLD has contributed significantly to increased overall, as well as cardiovascular and liver-related, mortality in the general population. In view of rapid advances in research into NAFLD in recent years, this consensus statement provides a brief update on the progress in the field and suggests preferred approaches for the comprehensive management of NAFLD and its related metabolic diseases.
引用
收藏
页码:406 / 415
页数:10
相关论文
共 61 条
[1]   The natural history of nonalcoholic fatty liver disease: A population-based cohort study [J].
Adams, LA ;
Lymp, JF ;
St Sauver, J ;
Sanderson, SO ;
Lindor, KD ;
Feldstein, A ;
Angulo, P .
GASTROENTEROLOGY, 2005, 129 (01) :113-121
[2]   NAFLD as a Risk Factor for the Development of Diabetes and the Metabolic Syndrome: An Eleven-Year Follow-up Study [J].
Adams, Leon A. ;
Waters, Oliver R. ;
Knuiman, Matthew W. ;
Elliott, Robert R. ;
Olynyk, John K. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (04) :861-867
[3]   Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis [J].
Aithal, Guruprasad P. ;
Thomas, James A. ;
Kaye, Philip V. ;
Lawson, Adam ;
Ryder, Stephen D. ;
Spendlove, Ian ;
Austin, Andrew S. ;
Freeman, Jan G. ;
Morgan, Linda ;
Weeber, Jonathan .
GASTROENTEROLOGY, 2008, 135 (04) :1176-1184
[4]   New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD) [J].
Ali, Rafeeq ;
Cusi, Kenneth .
ANNALS OF MEDICINE, 2009, 41 (04) :265-278
[5]  
AMERICAN DA, 2013, DIABETES CARE S1, V36, pS11, DOI DOI 10.2337/DC13-S011
[6]   GI Epidemiology: nonalcoholic fatty liver disease [J].
Angulo, P. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (08) :883-889
[7]   Nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. ;
Wong, Vincent W. -S. ;
Nobili, Valerio ;
Day, Christopher P. ;
Sookoian, Silvia ;
Maher, Jacquelyn J. ;
Bugianesi, Elisabetta ;
Sirlin, Claude B. ;
Neuschwander-Tetri, BrentA. ;
Rinella, Mary E. .
NATURE REVIEWS DISEASE PRIMERS, 2015, 1
[8]  
[Anonymous], 2002, Gastroenterology, V123, P1702
[9]   Nonalcoholic fatty liver disease and vascular risk [J].
Bhatia, Lokpal S. ;
Curzen, Nicholas P. ;
Byrne, Christopher D. .
CURRENT OPINION IN CARDIOLOGY, 2012, 27 (04) :420-428
[10]   The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association [J].
Chalasani, Naga ;
Younossi, Zobair ;
Lavine, Joel E. ;
Diehl, Anna Mae ;
Brunt, Elizabeth M. ;
Cusi, Kenneth ;
Charlton, Michael ;
Sanyal, Arun J. .
HEPATOLOGY, 2012, 55 (06) :2005-2023